EVALUATING THE FIRST RESULTS OF THE VALUE OF PSA DENSITY, PERCENTAGE OF FREE PSA, PERCENTAGE OF P2PSA AND PHI IN PROSTATE CANCER DIAGNOSIS AMONG PATIENTS WITH PROSTATE TUMOR
Main Article Content
Abstract
Background: Prostate cancer is a common cancer of men. According to Globocan 2018, the incidence and death rate of this cancer are respective ranking 2ndand 5th among the 10 most common cancers of men in the world. In Vietnam, prostate cancer is respective ranking 5th among 10 common cancers of men. Objectives: (1) Determine the value of PSA density, percentage of free PSA, percentage of p2PSA and prostate health index in diagnosis of prostate cancer. (2) Investigate the correlation between PSA density, percentage of free PSA, percentage of p2PSA and prostate health index with histopathological results in diagnosis of prostate cancer. Materials and methods: With 35 patients who were examined and treated with doubtful diagnosis of prostate cancer. Results: PHI index has the largest area under the ROC curve of 0.958 (CI 95%: 0.898-1.000); next is the PSA density of 0.861 (CI 95%: 0.676-1.000); percentage of free PSA is 0.701 (CI 95%: 0.446-0.957) and percentage of p2PSA has the smallest area under the ROC curve of 0.609 (CI 95%: 0.322-0.896). All 4 parameters are PSA density, percentage of free PSA, percentage of p2PSA and PHI have almost no correlation with Gleason score (correlation coefficient are respectively 0,469, 0,076, -0,406, 0,025 with p>0.05). Conclusion: PSA density and PHI are two good indicators used to diagnose prostate cancer. However, the cut-off point of PSA density and PHI are quite high.
Article Details
Keywords
prostate cancer, p2PSA test, PHI
References
2. Nguyễn Thị Duyên (2018), “Đánh giá giá trị nồng độ p2PSA huyết thanh và chỉ số PHI trong ung thư biểu mô tuyến tiền liệt”, Luận văn thạc sỹ y học, Đại Học Y Hà Nội.
3. Nguyễn Văn Mão (2016), “Nghiên cứu một số đặc điểm về tuổi, siêu âm và mối liên quan giữa mật độ PSA với mô bệnh học ở bệnh nhân u tiền liệt tuyến”, Tạp chí Y Dược Học Trường Đại học Y Dược Huế, 32, tr.35-42.
4. Nguyễn Thị Hồng Nhung (2015), “Nghiên cứu nâng cao hiệu quả của xét nghiệm PSA (Prostate specific antigen) huyết thanh trong tầm soát và chẩn đoán ung thư tuyến tiền liệt”, Luận văn Tiến sĩ Sinh Học, Đại Học Quốc Gia Thành phố Hồ Chí Minh.
5. Nguyễn Ngọc Rạng (2012), “Ứng dụng đường cong ROC”, Thiết Kế Nghiên Cứu & Thống Kê Y Học, Nhà xuất Bản Y Học.
6. Abdelgadir AE, Haala MG, Ghada A., Bader El-din HE (2014), “Use of free to total prostatespecific antigen ratio to improve differentiation of prostate cancer from benign prostate hyperplasia”, Egyptian Academic Journal of Biological Sciences, 6(1),151-156.
7. Beckman Coulter (2018), “Access Hybritech p2PSA”, Instruction For Use.
8. Beckman Coulter (2018), “Access Hybritech PSA”, Instruction For Use.
9. Beckman Coulter (2018), “Access Hybritech Free PSA”, Instruction For Use.
10. Bray F, Ferlay J, et al (2018), “Global cancer statistics 2018: Globocan Estimates of Incedence and Mortality Worldwide for 36 Cancers in 185 Countries”, CA Cancer J Clin, 68, pp.394-424.
11. Chiu PK-F, et al (2016), “Prostate Health Index and %p2PSA Predict Aggressive ProstateCancer Pathology in Chinese Patients Undergoing RadicalProstatectomy”, Ann Surg Oncol.
12. Epstein JI, Netto GJ (2015), “Clinical Correlates with Biospy: Serum Prostate-Specific Antigen, Digital Rectal Examination, and imaging Techniques”, Biopsy Interpretation Series: Biopsy Interpretation of the Prostate, 5th Edition, pp.1-7.
13. Lerner S.E., Jacobsen S.J, et al (1996), “Free, complexed and total serum PSA concentration and their proportions in predicting stage, grade, and DNA ploidy inpatients with prostate cancer”, The Journal of Urology, 55, 416.
14. Sokoll LJ, Wang Y, et al (2008), “[-2] proenzyme prostate-specific antigen for prostate cancer detection: A National Cancer Institute Early Dectection Research Network validation study”, The Journal of Urology, 180, pp. 539-543.